Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALT Altimmune, Inc.

Market Closed 01-16 16:00:00 EST

4.24

+0.00

0.00%

盘后4.24

+0.000.00%

19:57 EST

High4.37	Low4.17	Vol2.60M
Open4.30	D1 Closing4.24	Amplitude4.72%
Mkt Cap442.41M	Tradable Cap440.96M	Total Shares104.34M
T/O11.10M	T/O Rate2.50%	Tradable Shares104.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALT","market":"US","secType":"STK","nameCN":"Altimmune, Inc.","latestPrice":4.24,"timestamp":1768597200000,"preClose":4.24,"halted":0,"volume":2598239,"hourTrading":{"tag":"盘后","latestPrice":4.24,"preClose":4.24,"latestTime":"19:57 EST","volume":74758,"amount":317409.6924,"timestamp":1768611422860},"delay":0,"floatShares":104000000,"shares":104342385,"eps":-1.056106,"marketStatus":"Market Closed","change":0,"latestTime":"01-16 16:00:00 EST","open":4.3,"high":4.37,"low":4.17,"amount":11102519.481466,"amplitude":0.04717,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.056106,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.24,"preHourTrading":{"tag":"盘前","latestPrice":4.28,"preClose":4.24,"latestTime":"09:28 EST","volume":18478,"amount":78005.20960399999,"timestamp":1768573693072},"postHourTrading":{"tag":"盘后","latestPrice":4.24,"preClose":4.24,"latestTime":"19:57 EST","volume":74758,"amount":317409.6924,"timestamp":1768611422860},"volumeRatio":0.798784,"impliedVol":0.7438,"impliedVolPercentile":0.0797},"requestUrl":"/m/hq/s/ALT/tweets","defaultTab":"tweets","newsList":[{"id":"2603099103","title":"CCL Industries to Acquire ALT Technologies, Expanding Automotive Safety Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2603099103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603099103?lang=en_us&edition=fundamental","pubTime":"2026-01-16 22:16","pubTimestamp":1768572985,"startTime":"0","endTime":"0","summary":"CCL Industries (A) ( ($TSE:CCL.A) ) has shared an announcement. CCL Industries has signed a binding agreement to acquire Advanced Safety Technologi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ccl-industries-to-acquire-alt-technologies-expanding-automotive-safety-business?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ccl-industries-to-acquire-alt-technologies-expanding-automotive-safety-business?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4142","BK4588","LU2413666699.HKD","BK4121","BK4547","LU1878469433.USD","LU2092937221.SGD","BK4139","LU1543694498.USD","A","LU2041044095.USD","IE00BN0W2W23.USD","ALT","LU2413666426.HKD","LU2229751404.USD","LU1721428933.USD","BK4517","LU0347712357.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4567","LU1165135440.EUR","BK4599","CCL","LU2089279066.USD"],"gpt_icon":0},{"id":"2602074309","title":"Altimmune Director Wayne Pisano Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602074309","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602074309?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:10","pubTimestamp":1767993046,"startTime":"0","endTime":"0","summary":"Wayne Pisano, Director at Altimmune Inc., reported the acquisition of common shares of Altimmune Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL6kBvCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Altimmune Director Wayne Pisano Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","ALT","BK4139","BK4599"],"gpt_icon":0},{"id":"2601837412","title":"Owens & Minor Issues Amended Report on P&HS Business Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837412?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:27","pubTimestamp":1767648470,"startTime":"0","endTime":"0","summary":"Owens & Minor Inc., now operating as Accendra Health, Inc., has issued an amendment to its current report detailing the unaudited pro forma condensed consolidated financial information related to the sale of its Products & Healthcare Services business. The amendment outlines the financial effects of the $375 million transaction with Dominion Healthcare Acquisition Corporation and provides updated pro forma results for continuing operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Owens & Minor Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely resp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL7vHXgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","ACH","BK4175","BK4153","LU1878469433.USD","BK4139","BK4599"],"gpt_icon":0},{"id":"2601457837","title":"Altimmune Inc. Director Catherine A. Sohn Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601457837","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601457837?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:25","pubTimestamp":1767648346,"startTime":"0","endTime":"0","summary":"Catherine A. Sohn, Director at Altimmune Inc., reported the acquisition of common shares of Altimmune Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL5kDBmS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Altimmune Inc. Director Catherine A. Sohn Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","ALT","LU1878469433.USD","BK4139"],"gpt_icon":0},{"id":"2601313638","title":"BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2601313638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601313638?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:47","pubTimestamp":1767638851,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVAV","CNX","CVS","HAL","LBRT","SLB","SKYE","ALT","COP","RMTI","SPIR","MPC","HCA","WMB","LCID","HL","OMC","BAC","CRNX","LMT","SYF","GHRS","OKTA","QXO","EBC","BKR","NEM","NOC","SCCO","RIOT","ALB","CNC","BKSY","MBLY","EOG","SATL","AVY","INCY","ANET","DPZ"],"gpt_icon":1},{"id":"2601838540","title":"Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2601838540","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601838540?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:09","pubTimestamp":1767625740,"startTime":"0","endTime":"0","summary":"U.S. stocks were higher, with the Dow Jones index gaining more than 500 points on Monday.Shares of Altimmune Inc  rose sharply during Monday's session after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH.Altimmune shares jumped 23.6% to $4.34 on Monday.Here are some other big stocks recording gains in today’s session.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/05/Section-Of-A-Financial-Newspaper-Titled-_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49694843/altimmune-gh-research-gyre-therapeutics-and-other-big-stocks-moving-higher-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49694843/altimmune-gh-research-gyre-therapeutics-and-other-big-stocks-moving-higher-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4196","BK4551","BK4535","BK4588","BK4599","ALT","GH","LU1878469433.USD","BK4585","BK4139","GYRE"],"gpt_icon":0},{"id":"2601887952","title":"Shares of Altimmune Rise 21.4% After US FDA's 'Breakthrough' Tag for Liver Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601887952?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:31","pubTimestamp":1767623513,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60V5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4139","ALT","BK4599"],"gpt_icon":0},{"id":"2601460882","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive","url":"https://stock-news.laohu8.com/highlight/detail?id=2601460882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601460882?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:14","pubTimestamp":1767622447,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCCO","EOG","FIVN","MBLY","ARDT","THC","SLB","GOOGL","INCY","OKTA","RMTI","SPIR","BKSY","ALRS","BKR","IBM","HL","DUOL","COP","SGHT","CDE","HCA","DVN","OMC","SKYE","NEM","NMRA","EBC","GHRS","ANET","KBR","FTV","RIOT","SATL","LBRT","AZO","ALB","HAL","ALT","STX"],"gpt_icon":1},{"id":"2601889100","title":"BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889100","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889100?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:50","pubTimestamp":1767617454,"startTime":"0","endTime":"0","summary":"BUZZ-Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug** Shares of drug developer Altimmune ALT.O rise 12.8% to $3.96 premarket** ALT says U.S. FDA has granted \"breakthrough therapy\" tag for its experimental drug to treat patients with a type of liver disease** The drug, pemvidutide, is being tested in patients with metabolic dysfunction-associated steatohepatitis or MASH — a serious liver disease that develops when fat buildup causes inflammation of the organ** The breakthrough therapy tag is meant to speed up development and review of drugs to treat serious conditions or those with unmet medical needs** Co says it plans to initiate a late-stage trial evaluating multiple pemvidutide doses over a 52-week treatment period** In last 12 months, stock down 2.8%   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y60TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4139","ALT","BK4599"],"gpt_icon":0},{"id":"2601898348","title":"Altimmune Earns FDA Breakthrough Therapy Designation for Pemvidutide in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2601898348","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601898348?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:31","pubTimestamp":1767616267,"startTime":"0","endTime":"0","summary":"Altimmune Inc. has announced that the U.S. Food and Drug Administration  has granted Breakthrough Therapy Designation for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of metabolic dysfunction-associated steatohepatitis . The designation was based on 24-week data from the IMPACT Phase 2b trial, which demonstrated statistically significant MASH resolution without worsening of fibrosis, as well as early and substantial improvements in liver fat and non-invasive tests of fibrosis and hepatic inflammation. In December 2025, Altimmune reported 48-week topline data showing continued statistically significant improvements versus placebo in key non-invasive tests, further weight loss, and a favorable tolerability profile. The company plans to initiate a Phase 3 trial evaluating multiple pemvidutide doses over a 52-week treatment period, incorporating biopsy-based endpoints and the use of AIM-MASH AI Assist, an FDA-qualified AI pathology tool.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2CVwZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","BK4139","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","BK4599","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","ALT","IE00BKPKM429.USD","BK4588","LU0314104364.USD","LU1878469433.USD","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2601886743","title":"Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2601886743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601886743?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2GRZNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4599","BK4139","ALT"],"gpt_icon":0},{"id":"2595758400","title":"Altimmune Director Diane Jorkasky Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758400","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758400?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:10","pubTimestamp":1767042637,"startTime":"0","endTime":"0","summary":"Diane Jorkasky, Director, reported the acquisition of common shares of Altimmune Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDLc1VNw6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Altimmune Director Diane Jorkasky Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","ALT","LU1878469433.USD","BK4139"],"gpt_icon":0},{"id":"2594220740","title":"Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2594220740","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594220740?lang=en_us&edition=fundamental","pubTime":"2025-12-28 20:11","pubTimestamp":1766923862,"startTime":"0","endTime":"0","summary":"Even if it's not a huge purchase, we think it was good to see that Jerome Durso, the Independent Chairman of Altimmune...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/insider-buying-altimmune-independent-chairman-bought-us52k-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alt/altimmune/news/insider-buying-altimmune-independent-chairman-bought-us52k-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","ALT","LU1878469433.USD","BK4139"],"gpt_icon":0},{"id":"2593458649","title":"Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458649","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593458649?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:11","pubTimestamp":1766437876,"startTime":"0","endTime":"0","summary":"Jerome Benedict Durso, a Director at Altimmune Inc., has reported the acquisition of common shares of Altimmune Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7CxnNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4599","BK4139","LU1878469433.USD"],"gpt_icon":0},{"id":"2592160651","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160651?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:09","pubTimestamp":1766153366,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks,RedwireEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL6N3XP0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LMT","ETN","NVDS.UK","LYFT","NVDS","IE00BFXG0V08.USD","NVDY","LU1821325948.USD","NVIW.SI","LU1169589451.USD","WYFI","LU1868836914.USD","ACN","LU2756315664.SGD","PCAR","LU1868836591.USD","PANW","LUNR","MRK","NVDD","NVD2.UK","UUUU","3NVD.UK","NVDX","NVDU","BA","LU1868837136.USD","ALT","2NVD.UK","LU1691799644.USD","NVD3.UK","SNVD.UK","BK4535","NVD","IE0002141913.USD","RDW","LU2264538146.SGD","RIOT","EVAX","BTBT","AGCO"],"gpt_icon":1},{"id":"2592744166","title":"Altimmune's drug for a type of liver disease shows benefits in mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592744166","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592744166?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:39","pubTimestamp":1766144362,"startTime":"0","endTime":"0","summary":"Altimmune's drug for a type of liver disease shows benefits in mid-stage studyDec 19 (Reuters) - Altimmune ALT.O said on Friday its experimental drug improved signs of liver scarring and liver health ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL4N3XP0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","ALT","BK4139","BK4599"],"gpt_icon":0},{"id":"2592166417","title":"Altimmune Shares Climb 6.9% Premarket After Positive Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166417?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:35","pubTimestamp":1766144153,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","ALT","LU1878469433.USD","BK4139"],"gpt_icon":0},{"id":"2592166178","title":"Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166178","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166178?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:30","pubTimestamp":1766143823,"startTime":"0","endTime":"0","summary":"Altimmune Inc. announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis  at 48 weeks. The trial demonstrated improvements in key non-invasive markers of fibrosis across treatment arms compared to placebo, with continued reductions from the 24-week timepoint. Additional weight loss was observed from 24 to 48 weeks with the 1.8 mg dose, without plateauing. Pemvidutide maintained a favorable tolerability profile at 48 weeks, with a low treatment-related discontinuation rate. Following an end-of-Phase 2 meeting with the FDA, Altimmune plans to advance pemvidutide to a registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis, expected to begin in 2026. The 48-week Phase 2b data were presented during a conference call and webcast on December 19, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL67VzZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014039.USD","BK4599","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014005.SGD","ALT","IE00BGHQF748.EUR","LU1878469433.USD","BK4585","BK4139","LU2210149790.SGD","BK4588","SG9999014013.SGD","BK4112","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2592516615","title":"Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2592516615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592516615?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:30","pubTimestamp":1766143800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA3FYZSR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","BK4599","BK4139","ALT"],"gpt_icon":0},{"id":"2592166165","title":"Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166165?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:30","pubTimestamp":1766143800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA3FYZSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","ALT","BK4139","BK4599"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.altimmune.com","stockEarnings":[{"period":"1week","weight":0.0547},{"period":"1month","weight":-0.167},{"period":"3month","weight":0.107},{"period":"6month","weight":0.0392},{"period":"1year","weight":-0.3681},{"period":"ytd","weight":0.1745}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.421053,"avgChangeRate":0.001497},{"month":2,"riseRate":0.388889,"avgChangeRate":0.000059},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.052418},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.049636},{"month":5,"riseRate":0.5,"avgChangeRate":0.064208},{"month":6,"riseRate":0.388889,"avgChangeRate":-0.000157},{"month":7,"riseRate":0.388889,"avgChangeRate":0.041853},{"month":8,"riseRate":0.444444,"avgChangeRate":0.10411},{"month":9,"riseRate":0.210526,"avgChangeRate":-0.115822},{"month":10,"riseRate":0.263158,"avgChangeRate":0.032599},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.007448},{"month":12,"riseRate":0.526316,"avgChangeRate":0.184275}],"exchange":"NASDAQ","name":"Altimmune, Inc.","nameEN":"Altimmune, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Altimmune, Inc.,ALT,Altimmune, Inc.股票,Altimmune, Inc.股票老虎,Altimmune, Inc.股票老虎国际,Altimmune, Inc.行情,Altimmune, Inc.股票行情,Altimmune, Inc.股价,Altimmune, Inc.股市,Altimmune, Inc.股票价格,Altimmune, Inc.股票交易,Altimmune, Inc.股票购买,Altimmune, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}